艾塞那肽治疗2型糖尿病的临床研究

摘要

目的观察艾塞那肽对二甲双胍及预混胰岛素治疗未能有效控制血糖的2型糖尿病患者的疗效.方法90例入选的2型糖尿病患者随机分为二甲双胍组、预混胰岛素组、二甲双胍联合预混胰岛素组，给予口服最大耐受剂量二甲双胍及胰岛素治疗至少2个月，在此基础上加用艾塞那肽注射液，观察3个月测量糖化血红蛋白(HbAlc)、空腹血糖(FBG)、餐后2h血糖(PBG)、BMI变化情况.结果三组患者在原方案基础上加用艾塞那肽注射液治疗3月后HbAlc、FPG和PPG、BMI均较前降低(P<0.05).结论使用艾塞那肽可改善T2DM患者的血糖和胰岛β细胞功能，并对降低体重有很好疗效.%　　Objective To evaluate the therapeutic effects of exenatide on type 2 diabetes. Methods 90 patients with type 2 diabetes(T2DM) were randomly divided into three groups: group 1(metformin), group 2(premixed insulin) and group 3(premixed insulin plus metformin). All of the groups oraled maximum tolerance dose metformin for at least two months, in addition the patients received Exenatide for three months, during observation detect the change of FPG, PPG, HbA1c, BMI. Results Compared with before treatment,3 months after treatment patients, FPG, PPG, HbA1c and BMI were significantly descend(P<0.05). Conclusion Exenatide improves glucose control and β-cell function in T2DM patients, and decreases weight loss.